Impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer
Carregando...
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2018
Editora
SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JORNAL BRASILEIRO DE PNEUMOLOGIA, v.44, n.6, p.469-476, 2018
Resumo
Objetivo: Avaliar o impacto da radioterapia torácica na função respiratória e capacidade de exercício em pacientes com câncer de mama. Métodos: Pacientes com câncer de mama com indicação de radioterapia torácica após tratamento cirúrgico e quimioterápico foram submetidas a TCAR, avaliação respiratória e avaliação da capacidade de exercício antes da radioterapia torácica e três meses após o término do tratamento. Foram realizados teste de força muscular respiratória, medição da mobilidade torácica e prova de função pulmonar completa para a avaliação respiratória; realizou-se teste de exercício cardiopulmonar para avaliar a capacidade de exercício. A dose total de radioterapia foi de 50,4 Gy (1,8 Gy/fração) na mama ou na parede torácica, incluindo ou não a fossa supraclavicular (FSC). Histogramas dose-volume foram calculados para cada paciente com especial atenção para o volume pulmonar ipsilateral que recebeu 25 Gy (V25), em números absolutos e relativos, e a dose pulmonar média. Resultados: O estudo incluiu 37 pacientes. Após a radioterapia, observou-se diminuição significativa da força muscular respiratória, mobilidade torácica, capacidade de exercício e resultados da prova de função pulmonar (p < 0,05). A DLCO permaneceu inalterada. A TCAR mostrou alterações relacionadas à radioterapia em 87% das pacientes, o que foi mais evidente nas pacientes submetidas à irradiação da FSC. O V25% correlacionou-se significativamente com a pneumonite por radiação. Conclusões: Em nossa amostra de pacientes com câncer de mama, a radioterapia torácica parece ter causado perdas significativas na capacidade respiratória e de exercício, provavelmente por causa da restrição torácica; a irradiação da FSC representou um fator de risco adicional para o desenvolvimento de pneumonite por radiação.
Objective: To evaluate the impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer. Methods: Breast cancer patients in whom thoracic radiotherapy was indicated after surgical treatment and chemotherapy were submitted to HRCT, respiratory evaluation, and exercise capacity evaluation before radiotherapy and at three months after treatment completion. Respiratory muscle strength testing, measurement of chest wall mobility, and complete pulmonary function testing were performed for respiratory evaluation; cardiopulmonary exercise testing was performed to evaluate exercise capacity. The total radiotherapy dose was 50.4 Gy (1.8 Gy/fraction) to the breast or chest wall, including supraclavicular lymph nodes (SCLN) or not. Dose-volume histograms were calculated for each patient with special attention to the ipsilateral lung volume receiving 25 Gy (V25), in absolute and relative values, and mean lung dose. Results: The study comprised 37 patients. After radiotherapy, signifi cant decreases were observed in respiratory muscle strength, chest wall mobility, exercise capacity, and pulmonary function test results (p < 0.05). DLCO was unchanged. HRCT showed changes related to radiotherapy in 87% of the patients, which was more evident in the patients submitted to SCLN irradiation. V25% signifi cantly correlated with radiation pneumonitis. Conclusions: In our sample of patients with breast cancer, thoracic radiotherapy seemed to have caused signifi cant losses in respiratory and exercise capacity, probably due to chest wall restriction; SCLN irradiation represented an additional risk factor for the development of radiation pneumonitis
Objective: To evaluate the impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer. Methods: Breast cancer patients in whom thoracic radiotherapy was indicated after surgical treatment and chemotherapy were submitted to HRCT, respiratory evaluation, and exercise capacity evaluation before radiotherapy and at three months after treatment completion. Respiratory muscle strength testing, measurement of chest wall mobility, and complete pulmonary function testing were performed for respiratory evaluation; cardiopulmonary exercise testing was performed to evaluate exercise capacity. The total radiotherapy dose was 50.4 Gy (1.8 Gy/fraction) to the breast or chest wall, including supraclavicular lymph nodes (SCLN) or not. Dose-volume histograms were calculated for each patient with special attention to the ipsilateral lung volume receiving 25 Gy (V25), in absolute and relative values, and mean lung dose. Results: The study comprised 37 patients. After radiotherapy, signifi cant decreases were observed in respiratory muscle strength, chest wall mobility, exercise capacity, and pulmonary function test results (p < 0.05). DLCO was unchanged. HRCT showed changes related to radiotherapy in 87% of the patients, which was more evident in the patients submitted to SCLN irradiation. V25% signifi cantly correlated with radiation pneumonitis. Conclusions: In our sample of patients with breast cancer, thoracic radiotherapy seemed to have caused signifi cant losses in respiratory and exercise capacity, probably due to chest wall restriction; SCLN irradiation represented an additional risk factor for the development of radiation pneumonitis
Palavras-chave
Breast neoplasms, Radiotherapy, Radiation pneumonitis, Respiratory function tests, Exercise test, Neoplasias da mama, Radioterapia, Pneumonite por radiação, Testes de função respiratória, Teste de esforço
Referências
- Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548
- American Thoracic Society/ American College of Chest Physicians, 2003, AM J RESP CRIT CARE, V167, P212
- ARMSTRONG JG, 1995, ANN ONCOL, V6, P693, DOI 10.1093/oxfordjournals.annonc.a059286
- Azria D, 2004, BRIT J CANCER, V91, P1251, DOI 10.1038/sj.bjc.6602146
- Chopra RR, 2010, HEMATOL ONCOL CLIN N, V24, P625, DOI 10.1016/j.hoc.2010.03.009
- COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C
- Dimeo F, 2008, ANN ONCOL, V19, P1495, DOI 10.1093/annonc/mdn068
- Dunlap NE, 2010, INT J RADIAT ONCOL, V76, P796, DOI 10.1016/j.ijrobp.2009.02.027
- Erven K, 2012, INT J RADIAT ONCOL, V82, P701, DOI 10.1016/j.ijrobp.2010.12.058
- Evans ES, 2009, INTEGR CANCER THER, V8, P139, DOI 10.1177/1534735409335506
- Freedman GM, 2009, INT J RADIAT ONCOL, V74, P689, DOI 10.1016/j.ijrobp.2008.08.071
- Goldman UB, 2014, J RADIOTHER PRACT, V13, P211, DOI 10.1017/S1460396913000228
- Griffith K, 2009, CANCER-AM CANCER SOC, V115, P4874, DOI 10.1002/cncr.24551
- Hernberg M, 2002, INT J RADIAT ONCOL, V52, P128, DOI 10.1016/S0360-3016(01)01760-6
- Jaen J, 2006, INT J RADIAT ONCOL, V65, P1381, DOI 10.1016/j.ijrobp.2006.03.008
- Jarvenpaa R, 2006, ACTA ONCOL, V45, P16, DOI 10.1080/02841860500334921
- Kahan Z, 2007, INT J RADIAT ONCOL, V68, P673, DOI 10.1016/j.ijrobp.2006.12.016
- Kakizaki F, 1999, J CARDIOPULM REHABIL, V19, P390, DOI 10.1097/00008483-199911000-
- KINSELLA TJ, 1985, INT J RADIAT ONCOL, V11, P1579, DOI 10.1016/0360-3016(85)90209-3
- Kovelis Demetria, 2008, J. bras. pneumol., V34, P1008, DOI 10.1590/S1806-37132008001200005
- Krengli M, 2008, INT J RADIAT ONCOL, V70, P1460, DOI 10.1016/j.ijrobp.2007.08.050
- Kubo A, 2009, J MED INVESTIG, V56, P99, DOI 10.2152/jmi.56.99
- Markes M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005001
- Marks LB, 2010, INT J RADIAT ONCOL, V76, pS70, DOI 10.1016/j.ijrobp.2009.06.091
- Miller KL, 2005, INT J RADIAT ONCOL, V62, P1009, DOI 10.1016/j.ijdrobp.2004.12.054
- Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
- Minor GI, 2006, BREAST J, V12, P48, DOI 10.1111/j.1075-122X.2006.00180.x
- Mock V, 2001, CANCER PRACT, V9, P119, DOI 10.1046/j.1523-5394.2001.009003119.x
- Neder JA, 1999, BRAZ J MED BIOL RES, V32, P729, DOI 10.1590/S0100-879X1999000600008
- Neder JA, 1999, BRAZ J MED BIOL RES, V32, P703, DOI 10.1590/S0100-879X1999000600006
- Neder JA, 2001, AM J RESP CRIT CARE, V164, P1481, DOI 10.1164/ajrccm.164.8.2103007
- ODONNELL DE, 1994, CHEST, V106, P904, DOI 10.1378/chest.106.3.904
- Osako T, 2008, JPN J CLIN ONCOL, V38, P334, DOI 10.1093/jjco/hyn030
- Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401
- Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008
- Rancati T, 2007, RADIOTHER ONCOL, V82, P308, DOI 10.1016/j.radonc.2006.12.001
- Rodrigues G, 2004, RADIOTHER ONCOL, V71, P127, DOI 10.1016/j.radone.2004.02.015
- Ryan JL, 2007, ONCOLOGIST, V12, P22, DOI 10.1634/theoncologist.12-S1-22
- SCHRATTERSEHN AU, 1993, RADIOTHER ONCOL, V27, P198, DOI 10.1016/0167-8140(93)90074-I
- Segawa Y, 1997, INT J RADIAT ONCOL, V39, P91, DOI 10.1016/S0360-3016(97)00297-6
- Whelan TJ, 2000, CANCER, V88, P2260, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2260::AID-CNCR9>3.3.CO;2-D